Loading clinical trials...

Safety Study of ECO Conversion System For Red Blood Cells. | Clinical Trials | Clareo Health

COMPLETEDPhase 1NCT00261274

Safety Study of ECO Conversion System For Red Blood Cells.

The purpose of this study is to demonstrate that small amounts of a person's own red cells, when treated with an enzyme to make A-ECO Red Blood Cells, can be safely re-infused, repeatedly. Each partic...

Lead sponsor: Velico Medical•6 U.S. locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Related studies

RECRUITING

Familial Investigations of Childhood Cancer Predisposition

NCT03050268 · Acute Leukemia, Adenomatous Polyposis, and more

RECRUITINGPhase 2

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

NCT07039422 · Primary Immune Thrombocytopenia, Warm Autoimmune Hemolytic Anemia

RECRUITING

Registry Platform Myelofibrosis and Anemia

NCT06976918 · Primary Myelofibrosis, Secondary Myelofibrosis, and more

RECRUITING

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

NCT05012111 · Severe Aplastic Anemia, Telomere Biology Disorders, and more

RECRUITINGPhase 2

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

NCT03520647 · Severe Aplastic Anemia (SAA), Hypo-Plastic Myelodysplastic Syndrome (MDS), and more

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 27, 2020Terms

Trial snapshot

StatusCOMPLETED

PhasePHASE1

Enrollment60

Start dateNov 2005

Last updatedMay 27, 2020

Condition

Anemia

Locations shown

Yale New Haven Hospital

New Haven, Connecticut

University of Minnesota

Minneapolis, Minnesota

TriCore Reference Laboratories

Albuquerque, New Mexico

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 27, 2020Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Safety Study of ECO Conversion System For Red Blood Cells.

What this study is about

Clareo turns complex medical information into clear understanding you can use.

Sponsors

Related studies

Familial Investigations of Childhood Cancer Predisposition

Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic Anemia (wAIHA) Who Have Previously Benefited From Ianalumab

Registry Platform Myelofibrosis and Anemia

Natural History of Acquired and Inherited Bone Marrow Failure Syndromes

Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis

Trial snapshot

Condition

Locations shown

For caregivers